A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

Collier, KA; Valencia, H; Newton, H; Hade, EM; Sborov, DW; Cavaliere, R; Poi, M; Phelps, MA; Liva, SG; Coss, CC; Wang, J; Khountham, S; Monk, P; Shapiro, CL; Piekarz, R; Hofmeister, CC; Welling, DB; Mortazavi, A

Mortazavi, A (corresponding author), Ohio State Univ, Dept Internal Med, Div Med Oncol, Comprehens Canc Ctr, Columbus, OH 43210 USA.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 87 (5): 599

Abstract

Purpose Given clinical activity of AR-42, an oral histone deacetylase inhibitor, in hematologic malignancies and preclinical activity in solid tumors,......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索